News

AVaTAR MedTech Selected for One Six 8 Ventures Global MedTech Showcase

AVaTAR MedTech was selected from over 100 companies across more than 14 countries to present at the One Six 8 Ventures Global MedTech Showcase, highlighting our advancements in semilunar valve reconstruction.

Tomás Armendariz

November 12, 2025

AVaTAR MedTech at the 51st Argentine Congress of Cardiology

AVaTAR MedTech participated in the 51st Argentine Congress of Cardiology, where Dr. Ignacio Lugones presented advances in pediatric aortic valve reconstruction and engaged with leading specialists from across the region.

Tomás Armendariz

November 4, 2025

Showcasing Our Aortic Valve Repair Technology at TCT 2025 Innovation Sessions

AVaTAR MedTech presented its breakthrough in surgical aortic valve repair during the Innovation Session at TCT 2025, organized by the Cardiovascular Research Foundation and Fogarty Innovation.

Tomás Armendariz

October 29, 2025

AVaTAR MedTech Showcases at MIT’s Blueprint Fall 2025 Program

We participated in The Engine by MIT’s Blueprint Showcase, connecting with top leaders in Tough Tech and advancing our mission to turn medical innovation into meaningful impact.

Tomás Armendariz

October 27, 2025

AVaTAR MedTech Wins the 2025 SWPDC–AAP SOATT Pediatric Device Prize

AVaTAR MedTech was selected as a winner of the 2025 SWPDC–AAP SOATT Pediatric Device Prize, supporting the development and commercialization of our autologous trileaflet valve reconstruction tools for children with heart valve disease.

Tomás Armendariz

October 15, 2025

AVaTAR MedTech Selected by Buenos Aires City to Showcase at Project Qatar 2025

AVaTAR MedTech was selected by the Government of the City of Buenos Aires to participate in Project Qatar, gaining valuable insights and building strategic connections across the Middle Eastern healthcare and innovation ecosystem.

Tomás Armendariz

May 15, 2025

AVaTAR MedTech Completes the IDEA² Program at MIT linQ

AVaTAR MedTech successfully completed the IDEA² program at MIT linQ, strengthening its regulatory strategy, value proposition, and commercialization roadmap for life-changing pediatric heart valve solutions.

Tomás Armendariz

July 21, 2025

AVaTAR MedTech Presents at New York Valves 2025: The Structural Heart Summit

AVaTAR MedTech participated in New York Valves 2025, presenting its personalized valve reconstruction innovation during a dedicated session on cross-age structural heart solutions.

Tomás Armendariz

October 7, 2025

AVaTAR MedTech Wins the TCT Shark Tank Innovation Competition 2025 in Riyadh

AVaTAR MedTech was named the Winner of the TCT Shark Tank Innovation Competition 2025 at TCT Middle East in Riyadh, marking a new milestone in advancing life-saving, growth-accommodating valve reconstruction technology.‍

Tomás Armendariz

April 22, 2025

AVaTAR MedTech Wins Top Honor at Stanford’s Pediatric & Maternal Innovation Showcase

AVaTAR MedTech was awarded the Platinum Prize at the Stanford Pediatric & Maternal Innovation Showcase for its breakthrough technology enabling precise, growth-accommodating autologous valve reconstruction in pediatric cardiac surgery.

Tomás Armendariz

March 17, 2025

Driving Innovation: Our Progress Through Programs and Competitions

AVaTAR MedTech continues to gain global traction through competitive awards, prestigious accelerator programs, and international recognitions across the U.S., Europe, the Middle East, Canada, and Latin America. These achievements validate our mission to advance next-generation solutions in cardiac surgery.

Tomás Armendariz

December 12, 2025

AVaTAR: the company that saves lives

Argentina is fourth in the regional ranking of dynamic enterprises measured by ICSEd-Prodem. It is one of the most powerful countries in scientific-based projects and for the quality of its professionals. But funding in 2023 was the lowest since before the pandemic.‍

January 19, 2024

Technology, Innovation and Entrepreneurship: Celebrating the IGNITE Demo Day at the CABA Innovation Park

January 1, 2024

Financing, the pending issue of local ventures

January 31, 2024